|
Therapeutic Monoclonal Antibodies: World Market 2010-2025
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Our report gives you the following benefits in particular: • You will assess the current market for therapeutic monoclonal antibodies, as well as recent trends there • You will review the overall market area from 2010 to 2025, including global sales forecasts • You will receive forecasts for the main subgroups of the therapeutic mAbs market, showing you where opportunities for revenue growth will occur from 2010 onwards • You will receive sales forecasts for the leading products in this market from 2010 to 2025, with discussions of market potential and competition • You will receive sales forecasts for leading geographical markets from 2010 to 2025, with discussions and other supporting information • You will analyse the drivers, restraints, competition and opportunities influencing the market for therapeutic monoclonal antibodies from 2010 onwards • You will investigate under-met needs, with therapeutic requirements and commercial opportunities covered • You will discover the most exciting R&D pipeline developments in the sector • You will receive expert views on the sector, including full interview transcripts. 156 seiten | |||||||||||
| Inhalt der Studie: |
In 2009, the therapeutic monoclonal antibodies market generated total revenues of over $35bn worldwide. From 2010 onwards, this sector will benefit from new drugs and expanding indications for existin.....
In 2009, the therapeutic monoclonal antibodies market generated total revenues of over $35bn worldwide. From 2010 onwards, this sector will benefit from new drugs and expanding indications for existing products, our latest study shows. New technologies will be an important driver of revenue growth. Intensive R&D activity is producing a strong R&D pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. We expect significant opportunities for further commercial growth, as discussed in our latest report. Therapeutic Monoclonal Antibodies: World Market 2010-2025 explains how this market will develop, and where the commercial opportunities will lie. There remain high revenues to be made in this sector from 2010 to 2025. Our report explains where, why and by whom. What will be the characteristics of drugs that will succeed Avastin and Remicade? Will they become the blockbusters of the future? What are the potential applications and prospects for antibody fragments? Which R&D pipeline agents have most commercial promise? Our report will show you the outlook for this dynamic sector, providing information that will benefit your work, saving you time and aiding your decision making. Our report covers the following products in detail: • Avastin • Herceptin • MabThera • Erbitux • Remicade • Humira • Tysabri • Synagis • Lucentis • Xolair. What monoclonal antibodies are likely to enter the market from 2010 onwards, and will they dominate? How will patent expiry and biosimilar products influence the market? Where will the main opportunities lie, and what are the drivers and restraints in this industry and market? Our report will provide you with the information that you need to understand current trends and future directions in the market for therapeutic monoclonal antibodies. Comprehensive analysis of the industry and market for therapeutic mAbs Therapeutic Monoclonal Antibodies: World Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness primary and secondary research. This report provides sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 80 tables and figures included, as well as three interviews with experts. The result is a market- and industry-centred study, with detailed analyses and opinion to benefit your work. Report Highlights Companies Listed Abbott Laboratories Abgenix (acquired by Amgen, 2006) Ablynx Actinium Pharmaceuticals Affimed Therapeutics Alcon (Nestlé) Alexion Pharmaceuticals Alnylam Amgen Arana Therapeutics AstraZeneca Bayer HealthCare Biocon Biogen (merged with IDEC in 2003 to form Biogen Idec) Biogen Idec BioTech Pharma Biotest Boehringer Ingelheim Bradmer Pharmaceuticals Bristol-Myers Squibb (BMS) Cambridge Antibody Technology (CAT) (acquired by AstraZeneca) Cell Therapeutics Celltech (acquired by UCB, 2004) Center of Molecular Immunology [Cuba] Centocor Ortho Biotech (acquired by Johnson & Johnson, 1999) Cephalon Ception Therapeutics Chugai Pharmaceutical Co Committee for Medicinal Products for Human Use (CHMP) [EU] Corixa (acquired by GSK, 2005) Daiichi-Sankyo Dainippon Sumitomo Domantis (acquired by GSK, 2007) Dr. Reddy's Laboratories Eisai Pharmaceuticals Elan Corporation Eli Lilly and Company ESBATech ESTEVE Eurofarma Laboratorios European Medicines Agency (EMA, EMEA) Facet Biotech Food and Drug Administration (FDA) [US] Fresenius Genentech (acquired by Roche in 2009) Genmab Genzyme GlaxoSmithKline (GSK) GTC Biotherapeutics Health Canada Human Genome Sciences IDEC (merged with Biogen in 2003 to form Biogen Idec) Ilex Oncology (acquired by Genzyme, 2004) ImClone (acquired by Eli Lilly, November 2008) ImmunoGen Immunomedics Implicit Bioscience Johnson & Johnson Kyowa Hakko Kirin Laboratorio Elea LFB Biotechnologies Ludwig Institute for Cancer Research MacroGenics Medarex MedImmune (acquired by AstraZeneca, 2007) Menarini Merck & Co. Merck KGaA Merck Serono Micromet Millennium (acquired by Takeda, 2008) Ministry of Health, Labour and Welfare (MHLW) [Japan] Mitsubishi Tanabe Pharma Corporation Morphotek (acquired by Eisai, 2007) National Cancer Institute (NCI, part of NIH) [US] National Eye Institute (NEI, part of NIH) [US] National Institutes of Health (NIH) [US] NeuTec (acquired by Novartis, 2006) Novartis Nycomed Pharma Oncoscience Onyx Pharmaceuticals Osaka University Otsuka Pharmaceutical Co PDL BioPharma Peregrine Pharmaceuticals Pfizer Pierre Fabre Progenics Pharmaceuticals Ranbaxy Laboratories Rinat (acquired by Pfizer, 2006) Roche Roche Group (Roche, Genentech & Chugai) Sanofi-Aventis Schering-Plough Seattle Therapeutics Shanghai Medipharm Biotech (Medipharm) Shantha Biotechnics Southampton General Hospital [UK] Spectrum Pharmaceuticals State Food and Drug Administration (SFDA) [China] Takeda Pharmaceutical Company Tanox (acquired by Genentech in 2007) Tolerx TRION Pharma Tufts University UCB University of Massachusetts Medical School Viventia Biotechnologies Wilex Wyeth (now part of Pfizer) Xoma YM Biosciences Zenotech Laboratories Zenyaku Kogyo Co [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Monoclonal Antibody Market Review 1.2 Aims, Scope and Format of the Report 1.3 Research and Analysis Methods 2. Introduction to Monoclonal Antibodies 2.1 Antibodies 2.1.1 Function of Antibodies 2.1.2 Structure of Antibodies 2.2 Therapeutic Monoclonal Antibodies 2.2.1 Polyclonal and Monoclonal Antibodies 2.2.2 Murine Monoclonal Antibodies 2.2.3 Chimeric and Humanised Monoclonal Antibodies 2.2.4 Fully-Human Monoclonal Antibodies 2.2.5 Currently-Approved Monoclonal Antibody Therapies 3. World Therapeutic Monoclonal Antibodies Market, 2010-2025 3.1 Therapeutic Monoclonal Antibodies: Market Overview 3.1.1 The Therapeutic Monoclonal Antibody Market, 2009 3.1.2 Monoclonal Antibodies: Revenue Analysis by Therapeutic Area, 2009 3.1.3 Leading Therapeutic Monoclonal Antibodies, 2009 3.1.4 Monoclonal Antibodies: Revenue Analysis by Group, 2009 3.1.5 World Monoclonal Antibody Market: Overall Forecast, 2010-2015 3.1.6 World Monoclonal Antibody Market: Overall Forecast, 2015-2025 3.2 The Market for Anti-Cancer Monoclonal Antibodies 3.2.1 The Leading Anti-Cancer Monoclonal Antibodies, 2009 3.2.2 Anti-Cancer Monoclonal Antibodies: Revenue Analysis by Type, 2009 3.2.3 Anti-Cancer Monoclonal Antibodies: Revenue Analysis by Company, 2009 3.2.4 Anti-Cancer Monoclonal Antibodies Market, 2010-2015 3.2.5 Anti-Cancer Monoclonal Antibodies Market, 2015-2025 3.3 Avastin 3.3.1 Avastin: Cancer Blockbuster Set to Reach $10bn? 3.3.2 Avastin Revenue Analysis, 2009 3.3.3 Avastin 2010-2015: 'a Pipeline-in-One' 3.3.4 The Competitive Landscape for Avastin, 2010-2015 3.3.5 Avastin Market Forecast, 2010-2015 3.3.6 Outlook for Avastin: Sales Forecast, 2015-2025 3.4 Herceptin 3.4.1 Herceptin Successfully Targets HER2-Positive Patients 3.4.2 Herceptin Revenue Analysis, 2009 3.4.3 Herceptin Market Forecast, 2010-2015 3.4.4 Increased Competition for Herceptin, 2015-2025 3.5 MabThera/Rituxan 3.5.1 MabThera/Rituxan: The First Blockbuster Monoclonal Antibody 3.5.2 MabThera/Rituxan Revenue Analysis, 2009 3.5.3 MabThera/Rituxan Market Forecast, 2010-2015 3.5.4 MabThera/Rituxan Long-Term Prospects, 2015-2025 3.5.5 New Oncology Growth Areas for MabThera/Rituxan, 2010-2015 3.5.6 Intensifying Competition: MabThera/Rituxan in Cancer Treatment, 2015-2025 3.6 Erbitux 3.6.1 Erbitux' Oncology Indications 3.6.2 Erbitux Revenue Analysis, 2009 3.6.3 Opportunities in Head and Neck Cancer and New Indications for Erbitux 3.6.4 Erbitux Sales Forecast, 2010-2025 3.7 Other Monoclonal Antibodies for Treating Cancers 3.7.1 Vectibix 3.7.2 Campath/MabCampath 3.7.3 Zevalin 3.7.4 Bexxar 3.7.5 TheraCIM (Nimotuzumab) 3.7.6 Removab 3.8 The Autoimmune Disorder Monoclonal Antibodies Market 3.8.1 Leading Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis, 2009 3.8.2 Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis by Type, 2009 3.8.3 Remicade, Humira and Novel Antibodies Drive Autoimmune Monoclonal Market, 2010-2015 3.8.4 Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2015-2025 3.9 Remicade 3.9.1 Remicade: The Leading Monoclonal Antibody, 2009 3.9.2 Remicade Revenue Analysis, 2009 3.9.3 Remicade's Competitors 3.9.4 Imminent Increase in Competition for Remicade 3.9.5 Remicade Market Forecast, 2010-2015 3.9.6 Remicade Market Forecast, 2015-2025 3.10 Humira 3.10.1 Humira: First Fully-Human Monoclonal Antibody on the Market 3.10.2 Humira Revenue Analysis, 2009 3.10.3 Humira's Market Potential, 2010-2015 3.10.4 Humira Sales Forecast, 2015-2025 3.11 Tysabri 3.11.1 Tysabri - A Monoclonal Antibody for the Treatment of MS 3.11.2 Tysabri Revenue Analysis, 2009 3.11.3 Tysabri Sales Forecast, 2010-2025 3.11.4 Tysabri Will Face Competition from Oral MS Drugs 3.12 Xolair 3.12.1 Genentech's Asthma Monoclonal Antibody: Xolair 3.12.2 Xolair Revenue Analysis, 2009 3.12.3 Xolair Sales Forecast, 2010-2025 3.13 MabThera/Rituxan for Rheumatoid Arthritis 3.13.1 Competitors for MabThera/Rituxan in Autoimmune Disorders, 2010-2025 3.13.2 Prospects for Revenue Growth 3.14 Other Monoclonal Antibodies for Treating Autoimmune Disorders 3.14.1 Cimzia 3.14.2 Simponi 3.14.3 Soliris 3.14.4 Simulect 3.14.5 Actemra/RoActemra 3.14.6 Stelara 3.15 Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders) 3.15.1 Other Leading Monoclonal Antibodies: Revenue Analysis, 2009 3.15.2 Other Monoclonal Antibodies: Sales Forecast, 2010-2025 3.16 Synagis 3.16.1 Synagis: Blockbuster Respiratory Disorder Treatment 3.16.2 Synagis Revenue Analysis, 2009 3.16.3 Synagis Market Forecast, 2010-2025 3.17 Lucentis 3.17.1 Lucentis: Antibody Fragment for Ophthalmology 3.17.2 Lucentis Revenue Analysis, 2009 3.17.3 Impact of Off-Label Avastin on Lucentis, 2010-2025 3.17.4 Lucentis Sales Forecast, 2010-2015 3.17.5 Lucentis Sales Forecast, 2015-2025 3.18 ReoPro 3.18.1 ReoPro: Cardiovascular Monoclonal Antibody Fragment 3.18.2 ReoPro Revenue Analysis, 2009 4. Leading National Markets for Monoclonal Antibody Therapies, 2010-2025 4.1 Regional Overview 4.1.1 Top Seven National Markets for Therapeutic Monoclonal Antibodies 4.2 The US Monoclonal Antibody Therapeutics Market 4.2.1 US Market in 2009 4.2.2 US Monoclonal Antibody Therapeutics Market, 2010-2025 4.3 The Japanese Monoclonal Antibody Therapeutics Market, 2010-2025 4.4 Leading European Monoclonal Antibody Therapeutics Markets, 2010-2025 4.5 Prospects for Therapeutic Monoclonal Sales in Emerging Markets, 2010-2025 5. The R&D Pipeline for Therapeutic Monoclonal Antibodies 5.1 Late-Stage Oncology Pipeline: Additional and Expanded Indications 5.1.1 Avastin 5.1.2 MabThera/Rituxan 5.1.3 Erbitux 5.1.4 Tysabri 5.2 Late-Stage Oncology Pipeline: Novel Entities 5.2.1 Farletuzumab (MORAb-003) 5.2.2 Figitumumab (CP-751871) 5.2.3 Galiximab 5.2.4 Ipilimumab 5.2.5 Ramucirumab (IMC 1121B) 5.2.6 Rencarex (WX-G250) 5.2.7 Zalutumumab (HuMax-EGFr) 5.2.8 Lumiliximab 5.2.9 Pertuzumab (R1273) 5.3 Late-Stage Autoimmune Disorder Pipeline: Additional and Expanded Indications 5.3.1 MabThera/Rituximab 5.3.2 Alemtuzumab for Multiple Sclerosis 5.4 Late-Stage Autoimmune Disorder Pipeline: New Entities 5.4.1 Benlysta (Belimumab) 5.4.2 Bapineuzumab (AAB-001) 5.4.3 Briakinumab (ABT-874) 5.4.4 Mycograb (Efungumab) 5.4.5 Ocrelizumab (R1594) 5.4.6 Otelixizumab (TRX4) 5.5 Other Monoclonal Antibodies Pipeline (Non-Oncology/Autoimmune Disorders) 5.5.1 Motavizumab 5.5.2 Lucentis 5.6 Early Stage Pipeline: Antibody Fragments 5.6.1 Development and Potential of Antibody Fragments 5.6.2 Ablynx' Nanobodies 5.6.3 Domantis' Domain Fragments 5.6.4 Genmab's UniBodies 5.6.5 ESBATech 5.6.6 Affimed's TandAbs and Flexibodies 5.6.7 Micromet's BiTE Antibody Platform 5.7 Early Stage Pipeline: Antibody-Drug Conjugates 5.7.1 The Future of Conjugated Antibodies 5.7.2 Seattle Therapeutics 5.7.3 ImmunoGen's TAP Technology 5.7.4 Neuradiab 6. Issues Affecting the Therapeutic Monoclonal Antibodies Industry and Market, 2010-2025 6.1 SWOT Analysis of the Therapeutic Monoclonal Antibodies Industry and Market 6.2 Commercial Strengths 6.2.1 Monoclonal Antibodies Have a Wide Range of Specific Targets 6.2.2 Chronic and Niche Diseases Generate High Revenues 6.2.3 Strong R&D Pipeline and Technological Advances, Including Manufacturing Improvements 6.2.4 Lower Risk of Adverse Events for Monoclonal Antibodies in Cancer Treatment 6.3 Commercial Weaknesses 6.3.1 Biosimilar Monoclonal Antibodies 6.3.2 Future Prospects for Biosimilar Monoclonal Antibodies 6.3.3 High Development Cost Limits Growth 6.3.4 Injections are the Main Mode of Administration 6.3.5 The Challenge of Immunogenicity Still Present 6.3.6 Competition is Fierce for Many Targets 6.3.7 Insufficient Efficacy of Anti-Cancer Monoclonal Antibodies as Monotherapy – a Concern 6.4 Commercial Opportunities 6.4.1 Increasing Cancer Prevalence – Expanding Treatment Populations 6.4.2 Autoimmune Disorder Prevalence and Under-Treatment 6.5 Commercial Threats 6.5.1 Reimbursement for Monoclonal Antibodies 6.5.2 High Profile Safety Cases Increase Regulatory Vigilance 6.5.3 Current Financial Limitations in Research and Development 7. Interviews with Experts on the Sector 7.1 Interview 1: Dr Janice M. Reichert 7.1.1 Major Challenges and Opportunities for Monoclonal Antibody Cancer Therapeutics 7.1.2 Side-Effects of Monoclonal Antibodies for Cancer 7.1.3 Future Developments and Pipelines 7.1.4 The Effect of Biosimilars 7.2 Interview 2: Dr David Blakey 7.2.1 The Future of Humanised and Fully-Human Antibodies 7.2.2 Therapeutic Antibody Fragments versus Full-Length Antibodies 7.2.3 Major Opportunities in Monoclonal Antibody Cancer Therapeutics 7.3 Interview 3: Dr Mark Cragg 7.3.1 How Do Monoclonal Antibodies Treat Cancer? 7.3.2 The Future of Different Monoclonal Antibody Types 7.3.3 Threats and Limitations 7.3.4 Opportunities 7.3.5 Will Side Effects Limit Growth? 7.3.6 Future Developments 8. Conclusions 8.1 Monoclonal Antibodies Account for Over 30% of Biologic Drug Revenues 8.2 Prospects for the Therapeutic Monoclonal Antibody Industry and Market 8.3 The Monoclonal Antibody R&D Pipeline 8.4 Recent High Growth Rates Set to Continue to 2015 8.5 Market Forecast from 2015 Onwards 8.6 Expansion into New Markets 8.7 Concluding Thoughts [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Monoclonal Antibody Technology, 2010 Table 2.2 Modes of Action for Therapeutic Monoclonal Antibodies, 2010 Table 2.3 Monoclonal Antibody Therapies Approved by US FDA, 1986-2003 Table 2.4 Monoclonal Antibody Therapies Approved by US FDA, 2003-2010 Table 3.1 Monoclonal Antibody Sales by Therapeutic Area, 2009 Table 3.2 Sales of Leading Therapeutic Monoclonal Antibodies, 2009 Table 3.3 Monoclonal Antibody Sales by Technology Type, 2009 Table 3.4 Sales of Monoclonal Antibodies by Antibody Type, 2009 Table 3.5 Therapeutic Monoclonal Antibody Market: Commercial Drivers & Restraints, 2010-2025 Table 3.6 Total Market, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies: Sales Forecasts, 2010-2015 Table 3.7 Total Market, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies: Sales Forecasts, 2016-2025 Table 3.8 Sales of Leading Anti-Cancer Monoclonal Antibodies, 2009 Table 3.9 Sales by Technology Type: Monoclonal Antibodies for Cancer Treatment, 2009 Table 3.10 Sales by Antibody Type: Monoclonal Antibodies for Cancer Treatment, 2009 Table 3.11 Sales by Marketing Company: Monoclonal Antibodies for Cancer Treatment, 2009 Table 3.12 Monoclonal Antibodies for Cancer Treatment: Commercial Drivers & Restraints, 2010-2025 Table 3.13 Avastin, Herceptin, MabThera/Rituxan, Erbitux & Total Oncology Monoclonal Antibodies: Sales Forecasts, 2010-2015 Table 3.14 Avastin, Herceptin, MabThera/Rituxan, Erbitux & Total Oncology Monoclonal Antibodies: Sales Forecasts, 2016-2025 Table 3.15 Avastin: Commercial Drivers & Restraints, 2010-2025 Table 3.16 Herceptin: Commercial Drivers & Restraints, 2010-2025 Table 3.17 MabThera/Rituxan Total: Oncology and Autoimmune Disorder Sales Forecasts, 2010-2015 Table 3.18 MabThera/Rituxan Total: Oncology and Autoimmune Disorder Sales Forecasts, 2016-2025 Table 3.19 MabThera/Rituxan: Commercial Drivers & Restraints, 2010-2025 Table 3.20 Erbitux: Commercial Drivers & Restraints, 2010-2025 Table 3.21 Sales of Leading Autoimmune Disorder Monoclonal Antibodies, 2009 Table 3.22 Sales by Technology Type: Autoimmune Disorder Monoclonal Antibodies, 2009 Table 3.23 Sales by Antibody Class: Autoimmune Disorder Monoclonal Antibodies, 2009 Table 3.24 Autoimmune Disorder Monoclonal Antibodies: Commercial Drivers & Restraints, 2010-2025 Table 3.25 Remicade, Humira, Tysabri, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies: Sales Forecasts, 2010-2015 Table 3.26 Remicade, Humira, Tysabri, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies: Sales Forecasts, 2016-2025 Table 3.27 Remicade: Commercial Drivers & Restraints, 2010-2025 Table 3.28 Approved Indications for Humira in the US, 2010 Table 3.29 Humira, Commercial Drivers & Restraints, 2010-2025 Table 3.30 Tysabri, Commercial Drivers & Restraints, 2010-2025 Table 3.31 Sales of Other Leading Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders), 2009 Table 3.32 Synagis, Lucentis and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies: Sales Forecasts, 2010-2015 Table 3.33 Synagis, Lucentis and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies: Sales Forecasts, 2016-2025 Table 3.34 Lucentis: Commercial Drivers & Restraints, 2010-2025 Table 4.1 Leading National Markets for Therapeutic Monoclonal Antibodies, 2009 Table 4.2 Leading National Markets for Therapeutic Monoclonal Antibodies: Sales Forecasts, 2010-2015 Table 4.3 Leading National Markets for Therapeutic Monoclonal Antibodies: Sales Forecasts, 2016-2025 Table 5.1 R&D Pipeline for mAb Cancer Treatments: Additional Indications for Avastin, 2010 Table 5.2 R&D Pipeline for mAb Cancer Treatments: Additional Indications for Approved Drugs (Other than Avastin), 2010 Table 5.3 R&D Pipeline for mAb Cancer Treatments: Selected New Entities in Phase III/Regulatory Submission, 2010 Table 5.4 Autoimmune Disorder R&D Pipeline: Selected New Entities in Phase III, 2010 Table 5.5 Antibody Fragment R&D Pipeline R&D, 2010 Table 5.6 Antibody-Cytotoxic Drug Conjugate R&D Pipeline: Part 1, 2010 Table 5.7 Antibody-Cytotoxic Drug Conjugate R&D Pipeline: Part 2, 2010 Table 6.1 SWOT Analysis of the Monoclonal Antibody Therapeutics Sector, 2010-2025 Table 6.2 Monoclonal Antibody Targets, 2010 Table 6.3 Expected Patent Expiries for Therapeutic Monoclonal Antibodies Table 6.4 Biosimilar Monoclonal Antibodies in Development, 2010 Figure 2.1 Antibody Structure Figure 3.1 Therapeutic Monoclonal Antibodies: Market Shares by Therapeutic Area, 2009 Figure 3.2 Leading Therapeutic Monoclonal Antibodies: Market Shares, 2009 Figure 3.3 Therapeutic Monoclonal Antibodies: Market Shares by Technology Type, 2009 Figure 3.4 Therapeutic Monoclonal Antibodies: Market Shares by Antibody Class, 2009 Figure 3.5 Therapeutic Monoclonal Antibodies: Overall World Sales Forecast, 2010-2025 Figure 3.6 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies: Sales Forecasts, 2010-2025 Figure 3.7 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies: Market Shares, 2010-2025 Figure 3.8 Monoclonal Antibodies for Cancer Treatment: Market Shares, 2009 Figure 3.9 Monoclonal Antibodies for Cancer Treatment: Market Shares by Technology Type, 2009 Figure 3.10 Monoclonal Antibodies for Cancer Treatment: Market Shares by Antibody Class, 2009 Figure 3.11 Monoclonal Antibodies for Cancer Treatment: Market Shares by Company, 2009 Figure 3.12 Monoclonal Antibodies for Cancer Treatment: Sales Forecast, 2010-2025 Figure 3.13 Monoclonal Antibodies for Cancer Treatment: Sales Breakdowns by Brand, 2009, 2015, 2020 and 2025 Figure 3.14 Avastin: Sales Forecast, 2010-2025 Figure 3.15 Herceptin: Sales Forecast, 2010-2025 Figure 3.16 MabThera/Rituxan: Total, Oncology and Autoimmune Disorder Sales Forecasts, 2010-2025 Figure 3.17 Erbitux: Sales Forecast, 2010-2025 Figure 3.18 Autoimmune Disorder Monoclonal Antibodies: Market Shares, 2009 Figure 3.19 Autoimmune Disorder Monoclonal Antibodies: Market Shares by Technology Type, 2009 Figure 3.20 Autoimmune Disorder Monoclonal Antibodies: Market Shares by Antibody Class, 2009 Figure 3.21 Autoimmune Disorder Monoclonal Antibodies: Sales Forecast, 2010-2025 Figure 3.22 Autoimmune Disorder Monoclonal Antibodies: Sales Breakdowns by Brand, 2009, 2015, 2020 and 2025 Figure 3.23 Remicade: Sales Forecast, 2010-2025 Figure 3.24 Humira: Sales Forecast, 2010-2025 Figure 3.25 Xolair: Sales Forecast, 2010-2025 Figure 3.26 Total Non-Oncology/Autoimmune Disorder Monoclonal Antibodies: Sales Forecast, 2010-2025 Figure 3.27 Synagis: Sales Forecast, 2010-2025 Figure 3.28 Lucentis: Sales Forecast, 2010-2025 Figure 4.1 Leading National Markets for Therapeutic Monoclonal Antibodies: Market Shares, 2009 Figure 4.2 Leading National Markets for Therapeutic Monoclonal Antibodies: Market Shares, 2015 Figure 4.3 Leading National Markets for Therapeutic Monoclonal Antibodies: Market Shares, 2025 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
